Summary
The insulin-antagonistic effect of growth hormone was characterized by infusing the hormone at three different infusion rates (6, 12 or 24 mU·kg−1·min−1) for one h in 11 healthy subjects. The insulin effect was measured with the euglycaemic clamp technique combined with D-(3-3H)-glucose infusion to evaluate glucose production and utilization. A control study with NaCl (154 mmol·l−1) infusion was also performed. The insulin levels during the clamps were similar in all studies (36±0.2 mU·l−1). Peak growth hormone levels were reached at 60 min (growth hormone 6mU·kg−1·h−1: 31±5; growth hormone 12 mU·kg−1·h−1: 52±4 and growth hormone 24 mU·kg−1·h−1: 102±8mU·l−1). The insulin-antagonistic effect of growth hormone started after ∼2 h, was maximal after 4–5 h (∼39% inhibition of glucose infusion rate between control and growth hormone 24 mU·kg−1·h−1) and lasted for 6–7 h after peak levels. The resistance was due to a less pronounced insulin effect both to inhibit glucose production and to stimulate glucose utilization. Growth hormone infusion of 12 mU·kg−1·h−1 induced a similar insulin-antagonistic effect as the higher infusion rate whereas 6 mU·kg−1·h−1 induced a smaller response with a duration of 1 h between 3–4 h after peak levels of growth hormone. The present study demonstrates that growth hormone levels similar to those frequently seen in Type 1 (insulin-dependent) diabetic patients during poor metabolic control or hypoglycaemia, have pronounced insulin-antagonistic effects. The effects starts after about 2–3 h, is maximal after 4–5 h and lasts for about 6–7 h. Both duration and inhibitory effect of growth hormone are related to the plasma levels, where a maximal effect is seen at about 50 mU·l−1 or higher.
Article PDF
Similar content being viewed by others
References
Sharp PS, Foley K, Vitelli F, Maneschi F, Kohner EM (1984) Growth hormone response to hyperinsulinaemia in insulin-dependent diabetics. Comparison of patients with and without retinopathy. Diab Med 1: 55–58
Bratusch-Marrain PR, Smith D, DeFronzo RA (1982) The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab 55: 973–982
Rizza RA, Mandarino LJ, Gerich JE (1982) Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31: 663–669
Sherwin RS, Schulman GA, Hendler R, Walesky M, Belous A, Tamborlane M (1983) Effect of growth hormone on oral glucose tolerance and circulating metabolic fuels in man. Diabetologia 24: 155–161
Kollind M, Adamson U, Lins PE, Efendic S (1987) Diabetogenic action of GH and cortisol in insulin-dependent diabetes mellitus. Aspects of the mechanisms behind the Somogyi phenomenon. Horm Metabol Res 19: 156–159
Johansen K, Hansen AaP (1969) High 24-hour level of serum growth hormone in juvenile diabetics. Br Med J 2: 356–357
Hayford JT, Danney MM, Hendrix JA, Thompson RG (1980) Integrated concentration of growth hormone in juvenile-onset diabetes. Diabetes 29: 391–398
Asplin CM, Faria ACS, Carlsen EC, Vaccaro VA, Barr RE, Iranmanesh A, Lee MM, Veldhuis JD, Evans WS (1989) Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. J Clin Endocrinol Metabol 69: 239–245
Press M, Tamborlane WV, Sherwin RS (1984) Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N Engl J Med 310: 810–815
Press M, Tamborlane WV, Sherwin RS (1986) Effect of insulin on growth hormone-induced metabolic derangements in diabetes. Metabolism 35: 956–959
Cryer PE, Gerich JE (1985) Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus. N Engl J Med 313: 232–241
Attvall S, Eriksson B-M, Fowelin J, von Schenck H, Lager I, Smith U (1987) Early posthypoglycemic insulin resistance in man is mainly an effect of ß-adrenergic stimulation. J Clin Invest 80: 437–442
De Feo P, Perriello G, Torlone E, Ventura MM, Santeusanio F, Brunetti P, Gerich JE, Bolli GB (1989) Demonstration of a role for growth hormone in glucose counterregulation. Am J Physiol 256: E835-E843
Boyle PI, Cryer PE (1991) Growth hormone, cortisol, or both are involved in defense against, but are not critical to recovery from hypoglycaemia. Am J Physiol 260: E395-E402
Fowelin J, Attvall S, von Schenck H, Smith U, Lager I (1989) Combined effect of growth hormone and cortisol on late posthypoglycemic insulin resistance in humans. Diabetes 38: 1357–1364
Fowelin J, Attvall S, von Schenck H, Smith U, Lager I (1990) Postprandial hyperglycaemia following a morning hypoglycaemia in Type 1 diabetes mellitus. Diab Med 7: 156–161
Bolli GB, Gerich JE (1984) The “dawn phenomenon” — a common occurrence in both non-insulin-dependent and insulindependent diabetes mellitus. N Engl J Med 310: 746–750
Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB (1990) Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33: 52–59
Lager I, Attvall S, Eriksson BM, von Schenck H, Smith U (1986) Studies on the insulin-antagonistic effect of catecholamines in normal man. Evidence for the importance of ß2-receptors. Diabetologia 29: 409–416
De Bodo RC, Steele R, Altszuler N, Dunn A, Bishop JS (1963) On the hormonal regulation of carbohydrate metabolism; studies with C14 glucose. Rec Prog Horm Res 19: 445–488
Cowan JS, Hetenyi G Jr (1971) Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method. Metabolism 20: 360–372
Radziuk J, Norwich KH, Vranic M (1978) Experimental validation of measurements of glucose turnover in nonsteady state. Am J Physiol 234: E84-E93
Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6: 65–70
Barett EJ, DeFronzo RA, Bevilacqua S, Ferrannini E (1982) Insulin resistance in diabetic ketoacidosis. Diabetes 31: 923–928
Yki-Järvinen H (1990) Acute and chronic effects of hyperglycaemia on glucose metabolism. Diabetologia 33: 579–585
Yki-Järvinen H, Koivisto VA (1984) Insulin sensitivity in newly diagnosed Type 1 diabetics after ketoacidosis and after three months of insulin therapy. J Clin Endocrinol Metabol 59: 371–378
Björgell P, Rosberg S, Isaksson O, Belfrage P (1984) The antilipolytic, insulin-like effect of growth hormone is caused by a net decrease of hormone-sensitive lipase phosphorylation. Endocrinology 115: 1151–1156
Rosenfeld RG, Wilson DM, Dollar LA, Bennett A, Hintz RL (1982) Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. J Clin Endocrinol Metab 54: 1033–1038
MacGorman LR, Rizza RA, Gerich JE (1981) Physiological concentrations of growth hormone exert insulin-like and insulin antagonistic effects on both hepatic and extrahepatic tissues in man. J Clin Endocrinol Metab 53: 556–559
Adamson U, Efendic S (1979) Insulin-like and diabetogenic effects of growth hormone in healthy subjects, diabetics, and low insulin responders. J Clin Endocrinol Metab 49: 456–461
Möller N, Jörgensen JOL, Schmitz O, Möller J, Christiansen JS, Alberti KGMM, Örskov H (1990) Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Physiol 258: E86-E91
Adamson U, Cerasi E (1975) Acute effects of exogenous growth hormone in man: time- and dose-bound modification of glucose tolerance and glucose-induced insulin release. Acta Endocrinol 80: 247–261
Rizza RA, Mandarino LJ, Gerich JE (1981) Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240: E630-E639
Nurjhan N, Campbell PJ, Kennedy FP, Miles JM, Gerich JE (1986) Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans. Diabetes 35: 1326–1331
Fowelin J, Attvall S, von Schenck H, Smith U, Lager I (1990) Characterization of the late posthypoglycemic insulin resistance in insulin-dependent diabetes mellitus. Metabolism 39: 822–826
Goodman HM (1970) Antilipolytic effects of growth hormone. Metabolism 19: 849–855
Nyberg G, Smith U (1977) Human adipose tissue in culture. VII. The long-term effect of growth hormone. Horm Metab Res 9: 22–27
Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet I: 785–789
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fowelin, J., Attvall, S., von Schenck, H. et al. Characterization of the insulin-antagonistic effect of growth hormone in man. Diabetologia 34, 500–506 (1991). https://doi.org/10.1007/BF00403286
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00403286